Cerebral Inc. executives told its clinicians that the company will pause prescribing controlled substances such as Adderall to treat attention-deficit hyperactivity disorder in new patients beginning Monday, the company said.

Cerebral’s co-founder and chief executive, Kyle Robertson, made the announcement in an email sent to staff on Wednesday, adding that the company will continue to treat existing ADHD patients.